parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.08 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (626 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	11 Parkinson's papers of 214	0.67
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 3573

receipt 3583: APLP1 in dopamine neurons, braak

power: full sample +0.01 (p 0.956, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.04 (p 0.861, n 18). could be the mix.
skeptic: leave-one-out range -0.11 to +0.14, sign flips 6; without severely affected donors +0.01 (p 0.956, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APLP1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3582: APLP1 in oligodendrocytes, braak

power: full sample -0.23 (p 0.365, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.34 (p 0.164, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.28 (p 0.261, n 18). could be the mix.
skeptic: leave-one-out range -0.38 to -0.14, sign flips 0; without severely affected donors -0.23 (p 0.365, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APLP1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts